GigOptix, Inc. (GGOX.OB) Appoints Frank Schneider to Board of Directors
GigOptix Inc., a leading supplier of electronic and electro-optic semiconductor products for fiber-optic communications systems, today announced the appointment of…
Blog
ZymoGenetics, Inc. (ZGEN) Initiates Phase 2 Clinical Trial for Hepatitis C Investigational Drug Treatment
ZymoGenetics Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human…
Lorus Therapeutics (LRUSF.OB) Explains Preliminary Short Form Prospectus Filing
The bio-pharmaceutical company Lorus Therapeutics filed a preliminary short form in Canada. The short form covers the provinces of Ontario,…
Cyberonics, Inc. (CYBX) Posts Record Sales and Profits
Cyberonics recently announced their 4th quarter and fiscal year results. The medical technology company has been gaining traction with their…
Ecosphere Technologies, Inc. (ESPH.OB) to Deploy Ozonix Systems to the Gulf
Diversified environmental services company, Ecosphere Technologies, Inc. announced Friday that the company will participate in remediation efforts related to the…
Anthera Pharmaceuticals, Inc. (ANTH) Announces Dr. Colin Hislop as Chief Medical Officer
Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, recently…
Genta Inc. (GETA.OB) Announces Combined Data of Early Endpoints from Phase 3 Trials of Genasense® in Advanced Melanoma
Yesterday, Genta Inc. announced the presentation of pooled results on early endpoints from their randomized Phase 3 trials of Genasense®…
Blyth, Inc. (BTH) Reports Higher First Quarter Earnings But Lowers Full Year Guidance
Blyth, Inc. reported net income of $4.5 million, or $0.51 per diluted share, in the first quarter of 2010 ending…
Vivakor, Inc. (VIVK.OB) Video Chart for Monday, June 7, 2010
VIVK is on radar now as a possible reversal play. The last two days have formed a bullish harami pattern…
Cellceutix Corp. (CTIX.OB) Expedites Autism Studies in Response to Public Support; Announces Completion of Two Required Safety Pharmacology Studies
Cellceutix Corp. was pleased to announce this morning its acknowledgement of the many emails, phone calls and letters received regarding…